Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Lexon acquires lung cancer assay via Cancer Diagnostic Inc purchase:

This article was originally published in Clinica

Executive Summary

Lexon, a diagnostic company in Tulsa, Oklahoma, has obtained exclusive rights to its Telomerase Assay, a patent-pending blood test for lung cancer, through the $200,000 acquisition of Cancer Diagnostic Inc (CDI), a division of the Plant City, Florida-based company, Utek. The assay came from research conducted at the University of Maryland, Baltimore Medical Center, by Dr Edward Highsmith, who will continue to oversee research and commercialisation. Lexon also owns exclusive rights to the Ebaf Assay, a blood test for colon cancer screening. The acquisition - in cash and notes - was made in lieu of the previously announced merger of CDI into Lexon and eliminates the requirement under the merger agreement to issue 500,000 shares to CDI.

You may also be interested in...

COVID-19 Vaccine 'Brexit Bonus' A Myth

The Pink Sheet explains the procedures underpinning the UK’s emergency use authorization of the Pfizer/BioNTech COVID-19 vaccine.

Warning Letter Close-Outs – November 2020

The US Food and Drug Administration posted two device-related closeout letters in November.

Jazz And PharmaMar’s Zepzelca Hits Buffers In ATLANTIS Study

Jazz and PharmaMar need to see what further data will be needed to convert their FDA authorization into a full approval following disappointing results in the ATLANTIS Phase III trial.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts